Obermatt
See Similar Stocks →

CareDx

NMQ:CDNA · US14167L1035
BiotechnologyMedium

360

81
Profit price100
Owner Earnings Yield1
Dividend Yield1
Price/Sales74
EV / Gross Profit95
Price/Book48
Return on Capital79
Cash Return on Capital93
Return on Equity88
EBIT Margin62
Gross Profitability98
Accruals78
Owner Earnings Margin91
Sales growth51
Profit Growth77
Long-Term EPS Growth94
Reinvestment73
Price momentum45
Debt load66
Refinancing74
Debt Payback1
Liquidity1
Analyst ratings13
Opinion Changes50
Price Target Upside6
Market mood54
Value Creation6/20not creating value
  • Creates more value than its capital costs
  • Owner earnings growing
  • Owner earnings per share growing
  • Reinvests at strong returns
  • Solid earnings base

What this means

CareDx doesn't consistently earn more than its cost of capital, so it isn't yet creating shareholder value.

Profile

CountryUSA
IndustryBiotechnology
SizeMedium
TypePublic Company
ExchangeNASDAQGM
Founded1998
Employees672
Websitecaredx.com
ISINUS14167L1035
Last UpdateApr 2, 2026
Indices
NASDAQ (USA)
Themes
Health DiagnosticsCardiovascularNephrologyHematologyGeneticsBiomedical EngineeringChronic DiseasesStem Cell TherapyOncologyBiotechnologyHealth CareInformation Technology

Description

CareDx, Inc. (CareDx), a precision medicine company, focuses on the discovery, development, and commercialization of clinically differentiated, high-value diagnostic solutions for transplant patients and caregivers. The company’s integrated solution…

Analysis

Quality compounder

CareDx, Inc. earns the quality_compounder label: good underlying economics priced fairly, with no obvious bargain or excess.

Valuation data is not available for this company.

Growth is moderate; the safety picture is adequate. The company scores 6/20 on our value-creation score: not creating value.

No flags apply to this company at this time: accounts, balance sheet, and cash quality all pass. A clean bill of health is meaningful, not just the absence of a warning. This analysis describes numbers; it is not investment advice.

Detailed & Historical Ranks

Deep dive into 15 detailed ranks and 3 years of history.

Current202520242023
Price/Sales
74
—
—
—
Price/Earnings
22
—
—
—
Price/Book
48
—
—
—
Dividend Yield
1
—
—
—
Value (overall)
32
—
—
—

Cells are coloured by rank band (red weak → green strong). Sentiment & 360° history begins 2023.

Similar Stocks

The companies this stock is ranked against.

Compare CareDx with its peers
Natera
NSQ:NTRA
39
CountryUSA
IndustryBiotechnology
SizeLarge
Full Stock Analysis →
PTC Therapeutics
NSQ:PTCT
12
CountryUSA
IndustryBiotechnology
SizeMedium
Full Stock Analysis →
Vera Therapeutics
NMQ:VERA
44
CountryUSA
IndustryBiotechnology
SizeSmall
Full Stock Analysis →
Praxis Precision Medicines
NSQ:PRAX
37
CountryUSA
IndustryBiotechnology
SizeSmall
Full Stock Analysis →
Edwards Lifesciences
NYQ:EW
55
CountryUSA
IndustryHealth Care Equipment & Supplies
SizeX-Large
Full Stock Analysis →
Seres Therapeutics
NSQ:MCRB
6
CountryUSA
IndustryBiotechnology
SizeSmall
Full Stock Analysis →

Make Sense of the Ranks

Every rank runs 1–100 against true peers. Higher is always better.

360° View
1 · Watch OutGood· 100
Value
1 · ExpensiveGood Value· 100
Quality
1 · Weak FundamentalsHigh Quality· 100
Growth
1 · Tough TimesHigh Growth· 100
Safety
1 · High LeverageWell-Financed· 100
Sentiment
1 · SkepticismPositive· 100
Learn More →